# Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19

> **NCT05501418** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ever Supreme Bio Technology Co., Ltd.** · enrollment: 75 (estimated)

## Conditions studied

- COVID-19 Infection

## Interventions

- **BIOLOGICAL:** Allogeneic umbilical cord mesenchymal stem cells
- **BIOLOGICAL:** Controlled normal saline

## Key facts

- **NCT ID:** NCT05501418
- **Lead sponsor:** Ever Supreme Bio Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-05
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501418, "Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05501418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*